Gene Signal International SA

ParcScientifique EPFL-A, EPFL/Swiss Technology Institute Lausanne, 1015 Lausanne, Switzerland
Tel: 004-121-804-6164 | Fax: 004-179-697-1300
Anti-VEGFs are today’s standard of care for the treatment of pathological ocular neovascularisation. Because they require intravitreal injections every 1-3 months however, additional needleless therapies are needed. Gene Signal may have such a drug. Aganirsen is an antisense DNA oligonucleotide that has demonstrated effectiveness in inhibiting neovascularisation topically (front of the eye) and in reaching and acting on the retina (back of the eye). Following a clean phase I , Aganirsen has demonstrated its efficacy in a phase II study of corneal neovascularisation , and is now in phase III for the same indication.

Find out more